Irinotecan Eugia

Irinotecan, the active ingredient in Irinotecan Eugia, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer and other solid tumours in adult patients, administered intravenously.

GNH USA supplies Irinotecan Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, pharmacies and clinics worldwide, adhering to rigorous quality assurance and regulatory standards. The company provides reliable cold‑chain logistics where required and supports regulatory documentation for importation.

Irinotecan is a topoisomerase I inhibitor used in oncology for specific solid tumours. - Metastatic colorectal cancer: improves survival as part of combination chemotherapy. - Advanced gastric cancer: used in combination regimens to control disease progression. - Small cell lung cancer: employed in second‑line therapy to achieve tumor response.

Irinotecan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count leading to infection risk. - Diarrhea: frequent loose stools that may be severe. - Nausea and vomiting: gastrointestinal upset common during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis: intense diarrhea with abdominal pain and risk of perforation. - Hepatic toxicity: elevated liver enzymes or jaundice indicating liver injury.

When using Irinotecan, clinicians should observe several safety measures to minimize risks. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: check enzymes before and during therapy. - Evaluate bowel status: identify pre‑existing diarrhea or obstruction. - Adjust dose in hepatic impairment: reduce dosage according to liver function. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in original container, protect from moisture and light.

Irinotecan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - Anticholinergic agents (e.g., atropine): may worsen diarrhea.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce drug levels. - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Live vaccines: avoid during treatment due to immunosuppression.